| P50 | author | Eastern Cooperative Oncology Group | Q5330089 |
| | Robert D Burk | Q56916578 |
| P2093 | author name string | Edie Weller | |
| | Gloria Ho | |
| | Carla I Falkson | |
| | Scott Wadler | |
| | Anna S Kadish | |
| | Yuexian Wang | |
| | Donna Levy | |
| | Helen L Frederickson | |
| P2860 | cites work | A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions | Q24599668 |
| | Nonparametric Estimation from Incomplete Observations | Q25938997 |
| | Cancer statistics, 2001 | Q28189339 |
| | Human papillomavirus is a necessary cause of invasive cervical cancer worldwide | Q29617514 |
| | The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product | Q29618372 |
| | Toxicity and response criteria of the Eastern Cooperative Oncology Group | Q29619399 |
| | Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras. | Q33559590 |
| | Differential effects of human papillomavirus type 6, 16, and 18 DNAs on immortalization and transformation of human cervical epithelial cells | Q33831719 |
| | Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group | Q34313864 |
| | Recent Progress in Defining the Epidemiology of Human Papillomavirus Infection and Cervical Neoplasia | Q35225570 |
| | Natural killer cell stimulatory factor (NKSF) or interleukin-12 is a key regulator of immune response and inflammation | Q35279873 |
| | The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines | Q37537138 |
| | Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers | Q37602239 |
| | A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection | Q37892308 |
| | Human papillomavirus infection and other risk factors for cervical neoplasia: a case-control study | Q39249937 |
| | The in vivo antiviral activity of interleukin-12 is mediated by gamma interferon | Q39872869 |
| | Antitumor activity of interleukin 12 in preclinical models | Q41079216 |
| | Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells | Q41532466 |
| | Antitumor and antimetastatic activity of interleukin 12 against murine tumors | Q41906195 |
| | Interleukin 12 induces stable priming for interferon gamma (IFN-gamma) production during differentiation of human T helper (Th) cells and transient IFN-gamma production in established Th2 cell clones | Q42070272 |
| | Interleukin-12 primes human CD4 and CD8 T cell clones for high production of both interferon-gamma and interleukin-10. | Q42943512 |
| | Cancer of the Uterine Cervix | Q56040205 |
| | Lack of efficacy of interferon-alpha therapy in recurrent, advanced cervical cancer | Q60197521 |
| | Persistent Genital Human Papillomavirus Infection as a Risk Factor for Persistent Cervical Dysplasia | Q60197523 |
| | Cell-mediated immune responses to E7 peptides of human papillomavirus (HPV) type 16 are dependent on the HPV type infecting the cervix whereas serological reactivity is not type-specific | Q72167468 |
| | Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors: implications for the immunotherapy of cancer | Q72663515 |
| | Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia | Q73689490 |
| | Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions | Q77845976 |
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cervix uterine cancer | Q160105 |
| | phase II clinical trial | Q42824440 |
| P304 | page(s) | 957-964 | |
| P577 | publication date | 2004-03-01 | |
| P1433 | published in | Gynecologic Oncology | Q5625182 |
| P1476 | title | A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96. | |
| P478 | volume | 92 | |